October 16, 2017 10:54 PM ET


Company Overview of PhaseBio Pharmaceuticals, Inc.

Company Overview

PhaseBio Pharmaceuticals, Inc. develops biotherapeutics to treat metabolic and cardiopulmonary disorders. Its development candidates include PE0139, a novel super-long-acting basal insulin-ELP fusion for weekly dosing; and PB1046, a weekly VIP receptor agonist for treatment of acute and chronic heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. PhaseBio Pharmaceuticals, Inc. was formerly known as Phase Bioscience, Inc. and changed its name to PhaseBio Pharmaceuticals, Inc. in October, 2006. The company was founded in 2002 and is based in Malvern, Pennsylvania.

One Great Valley Parkway

Suite 30

Malvern, PA 19355

United States

Founded in 2002





Key Executives for PhaseBio Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 52
Executive Chairman
Age: 49
Co-Founder and Director
Chief Financial Officer
Age: 52
Chief Medical Officer
Compensation as of Fiscal Year 2017.

PhaseBio Pharmaceuticals, Inc. Key Developments

PhaseBio Pharmaceuticals, Inc. Presents at FierceBiotech's 2nd Annual Drug Development Forum, Sep-25-2017

PhaseBio Pharmaceuticals, Inc. Presents at FierceBiotech's 2nd Annual Drug Development Forum, Sep-25-2017 . Venue: Renaissance Boston Waterfront Hotel, Boston, Massachusetts, United States. Speakers: John S. Lee, Chief Medical Officer.

PhaseBio Pharmaceuticals, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-05-2017 11:40 AM

PhaseBio Pharmaceuticals, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-05-2017 11:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Jonathan P. Mow, Chief Executive Officer and Director.

PhaseBio Pharmaceuticals, Inc. Announces Dosing of First Patients in Two-Part Phase 2a Study of PB1046 in Cardiopulmonary Disorders

PhaseBio Pharmaceuticals, Inc. announced the dosing of the first patients in Part One of a Phase 2a clinical study of PB1046, a once-weekly vasoactive intestinal peptide (VIP) receptor agonist in development for the treatment of cardiopulmonary disorders. Part One will assess PB1046 in adult subjects with stable heart failure with reduced ejection fraction. Part Two, which PhaseBio expects to initiate later in 2016, will examine PB1046 in subjects with cardiac dysfunction secondary to Duchenne muscular dystrophy. Part One is a randomized, double-blind, placebo-controlled, multiple-dose study evaluating the safety, tolerability, and pharmacokinetic and pharmacodynamic response following four weeks of once-weekly subcutaneous injections of PB1046 in 28 adults with heart failure. Dose levels shown to be safe and well-tolerated in Part One will be selected for evaluation in Part Two of the study. PB1046 is based on vasoactive intestinal peptide (VIP), a naturally occurring neuropeptide that exerts its physiological effects through activation of the G-protein coupled receptors VPAC1 and VPAC2, which are widely distributed throughout the cardiovascular, pulmonary and immune systems. To date, the inherently poor in vivo stability and bioavailability of the native peptide have limited its therapeutic use. PB1046 is a genetic fusion of an analogue of VIP with PhaseBio’s elastin-like polypeptide biopolymer, which overcomes these limitations and demonstrates prolonged circulatory drug exposure and potent activity. PB1046 was designed to be relatively selective in binding to the VPAC2 receptor to reduce potential gastrointestinal side effects believed to be associated with excessive activation of the VPAC1 receptor. PB1046 has been shown to be highly effective in animal models of hypertension, pulmonary arterial hypertension and heart failure, with positive cardiac inotropic (contractility) and lusitropic (relaxation) effects without an increase in myocardial oxygen demand. Additional pre-clinical data demonstrated that chronic administration of PB1046 in a murine model of DMD (mdx mouse) significantly slowed the deterioration of cardiac function. In a Phase 1 single-ascending-dose study, PB1046 was well-tolerated and demonstrated a prolonged, dose-dependent effect on blood pressure when administered subcutaneously to patients with essential hypertension. This supported a second Phase 1 single-ascending-dose study in patients with essential hypertension, in which PB1046 was administered intravenously to support use in an acute setting. PB1046 has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cardiomyopathy associated with dystrophinopathies.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
January 17, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PhaseBio Pharmaceuticals, Inc., please visit www.phasebio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.